MINNEAPOLIS, Oct. 14 /PRNewswire/ -- Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.
Under the agreement, Timm Medical will be responsible for promoting Prosed® DS to urologists and retail pharmacists in the United States. Ferring will continue to promote Prosed® DS to physicians in the United States and will retain responsibility for manufacturing, supply and regulatory affairs. Financial terms of the agreement were not disclosed.
Prosed® DS is a urinary analgesic, antiseptic and antispasmodic combination. Prosed® DS has a long history of use for the treatment of pain and discomfort of the lower urinary tract.
"We are excited to partner with Ferring Pharmaceuticals to promote this well-established treatment for urinary discomfort," commented David Talen, President of Timm Medical. "Timm Medical and Ferring Pharmaceuticals share a commitment to urologists and the care of their patients. Timm Medical's flagship product, the Osbon ErecAid, has a 30-year history of providing safe, effective and reliable treatment for men suffering from erectile dysfunction. Prosed® DS has the same outstanding reputation as an effective treatment for the pain associated with urological procedures, inflammatory diseases and infections, and represents a natural complement to our product portfolio."
About Timm Medical
Timm Medical is a specialist urology company owned by affiliates of Paul Capital Healthcare. Timm Medical offers products in the areas of erectile function and incontinence. Through its sales force in the United States, Timm calls on over 3,000 urology practices. In addition, Timm distributes products via a 6
|SOURCE Timm Medical Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved